<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37391799</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>03</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>04</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1478-6362</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jun</Month><Day>30</Day></PubDate></JournalIssue><Title>Arthritis research &amp; therapy</Title><ISOAbbreviation>Arthritis Res Ther</ISOAbbreviation></Journal><ArticleTitle>Deconvolution of whole blood transcriptomics identifies changes in immune cell composition in patients with systemic lupus erythematosus (SLE) treated with mycophenolate mofetil.</ArticleTitle><Pagination><StartPage>111</StartPage><MedlinePgn>111</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">111</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13075-023-03089-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Systemic lupus erythematosus (SLE) is a clinically and biologically heterogeneous autoimmune disease. We explored whether the deconvolution of whole blood transcriptomic data could identify differences in predicted immune cell frequency between active SLE patients, and whether these differences are associated with clinical features and/or medication use.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Patients with active SLE (BILAG-2004 Index) enrolled in the BILAG-Biologics Registry (BILAG-BR), prior to change in therapy, were studied as part of the MASTERPLANS Stratified Medicine consortium. Whole blood RNA-sequencing (RNA-seq) was conducted at enrolment into the registry. Data were deconvoluted using CIBERSORTx. Predicted immune cell frequencies were compared between active and inactive disease in the nine BILAG-2004 domains and according to immunosuppressant use (current and past).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Predicted cell frequency varied between 109 patients. Patients currently, or previously, exposed to mycophenolate mofetil (MMF) had fewer inactivated macrophages (0.435% vs 1.391%, p&#x2009;=&#x2009;0.001), na&#xef;ve CD4 T cells (0.961% vs 2.251%, p&#x2009;=&#x2009;0.002), and regulatory T cells (1.858% vs 3.574%, p&#x2009;=&#x2009;0.007), as well as a higher proportion of memory activated CD4 T cells (1.826% vs 1.113%, p&#x2009;=&#x2009;0.015), compared to patients never exposed to MMF. These differences remained statistically significant after adjusting for age, gender, ethnicity, disease duration, renal disease, and corticosteroid use. There were 2607 differentially expressed genes (DEGs) in patients exposed to MMF with over-representation of pathways relating to eosinophil function and erythrocyte development and function. Within CD4&#x2009;+&#x2009;T cells, there were fewer predicted DEGs related to MMF exposure. No significant differences were observed for the other conventional immunosuppressants nor between patients according disease activity in any of the nine organ domains.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">MMF has a significant and persisting effect on the whole blood transcriptomic signature in patients with SLE. This highlights the need to adequately adjust for background medication use in future studies using whole blood transcriptomics.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Akthar</LastName><ForeName>Mumina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Rheumatology Department, Sandwell and West Birmingham NHS Trust, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nair</LastName><ForeName>Nisha</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carter</LastName><ForeName>Lucy M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vital</LastName><ForeName>Edward M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sutton</LastName><ForeName>Emily</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Centre for Epidemiology Versus Arthritis, Division of Musculoskeletal &amp; Dermatological Sciences, The University of Manchester, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McHugh</LastName><ForeName>Neil</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Pharmacy and Pharmacology, University of Bath, Bath, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>British Isles Lupus Assessment Group Biologics Register (BILAG BR) Consortium</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>MASTERPLANS Consortium</CollectiveName></Author><Author ValidYN="Y"><LastName>Bruce</LastName><ForeName>Ian N</ForeName><Initials>IN</Initials><AffiliationInfo><Affiliation>Centre for Epidemiology Versus Arthritis, Division of Musculoskeletal &amp; Dermatological Sciences, The University of Manchester, Manchester, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reynolds</LastName><ForeName>John A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Rheumatology Department, Sandwell and West Birmingham NHS Trust, Birmingham, UK. j.a.reynolds.1@bham.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK. j.a.reynolds.1@bham.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Arthritis Res Ther</MedlineTA><NlmUniqueID>101154438</NlmUniqueID><ISSNLinking>1478-6354</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>HU9DX48N0T</RegistryNumber><NameOfSubstance UI="D009173">Mycophenolic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Arthritis Res Ther. 2023 Sep 4;25(1):160</RefSource><PMID Version="1">37667347</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009173" MajorTopicYN="N">Mycophenolic Acid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059467" MajorTopicYN="N">Transcriptome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001327" MajorTopicYN="Y">Autoimmune Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Deconvolution</Keyword><Keyword MajorTopicYN="N">Mycophenolate mofetil</Keyword><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword><Keyword MajorTopicYN="N">Transcriptomics</Keyword></KeywordList><CoiStatement>INB has received grant/research support from Genzyme/Sanofi, GlaxoSmithKline, Roche, and UCB; received consulting fees from Eli Lilly, GlaxoSmithKline, ILTOO, Merck Serono, and UCB; and was a speaker for AstraZeneca, GlaxoSmithKline, and UCB. EMV has received consultancy fees from Roche, GSK, AstraZeneca, Aurinia Pharmaceuticals, Lilly and Novartis. All other authors have declared no competing interests.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Gordon</LastName><ForeName>Patrick</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Young-Min</LastName><ForeName>Steven</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stevens</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Prabu</LastName><ForeName>Athiveer</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Batley</LastName><ForeName>Mike</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gendi</LastName><ForeName>Nagui</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dasgupta</LastName><ForeName>Bhaskar</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Khamashta</LastName><ForeName>Munther</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hewins</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stratton</LastName><ForeName>Richard J</ForeName><Initials>RJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chan</LastName><ForeName>Antoni</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>De Lord</LastName><ForeName>Denise</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>King</LastName><ForeName>Jon</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dubey</LastName><ForeName>Shirish</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>O'Riordan</LastName><ForeName>Edmond</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shaffu</LastName><ForeName>Shireen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laversuch</LastName><ForeName>Cathy</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sheeran</LastName><ForeName>Thomas P</ForeName><Initials>TP</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vermaak</LastName><ForeName>Erin</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Erb</LastName><ForeName>Nicola</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pyne</LastName><ForeName>Debasish</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jeffrey</LastName><ForeName>Rachel</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Youssef</LastName><ForeName>Hazem</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Al-Allaf</LastName><ForeName>Wahab</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Regan</LastName><ForeName>Marian</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaul</LastName><ForeName>Arvind</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Payne</LastName><ForeName>Katherine</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lunt</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Peek</LastName><ForeName>Niels</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Geifman</LastName><ForeName>Nophar</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gavan</LastName><ForeName>Sean</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Armitt</LastName><ForeName>Gillian</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doherty</LastName><ForeName>Patrick</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Prattley</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Azadbakht</LastName><ForeName>Narges</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Papazian</LastName><ForeName>Angela</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Le Sueur</LastName><ForeName>Helen</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farrelly</LastName><ForeName>Carmen</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Richardson</LastName><ForeName>Clare</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shabbir</LastName><ForeName>Zunnaira</ForeName><Initials>Z</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hewitt</LastName><ForeName>Lauren</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gordon</LastName><ForeName>Caroline</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Young</LastName><ForeName>Stephen</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jayne</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farewell</LastName><ForeName>Vern</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Su</LastName><ForeName>Li</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pickering</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lightstone</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gilmore</LastName><ForeName>Alyssa</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Botto</LastName><ForeName>Marina</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vyse</LastName><ForeName>Timothy</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morris</LastName><ForeName>David Lester</ForeName><Initials>DL</Initials></Investigator><Investigator ValidYN="Y"><LastName>D'Cruz</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wittmann</LastName><ForeName>Miriam</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Emery</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beresford</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hedrich</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Midgley</LastName><ForeName>Angela</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gritzfeld</LastName><ForeName>Jenna</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ehrenstein</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Isenberg</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parvaz</LastName><ForeName>Mariea</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dunnage</LastName><ForeName>Jane</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Batchelor</LastName><ForeName>Jane</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Holland</LastName><ForeName>Elaine</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Upsall</LastName><ForeName>Pauline</ForeName><Initials>P</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>3</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>1</Day><Hour>11</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>30</Day><Hour>23</Hour><Minute>40</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37391799</ArticleId><ArticleId IdType="pmc">PMC10311871</ArticleId><ArticleId IdType="doi">10.1186/s13075-023-03089-5</ArticleId><ArticleId IdType="pii">10.1186/s13075-023-03089-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Manson JJ, Rahman A. Systemic lupus erythematosus. Orphanet J Rare Dis. 2006;1:6. doi: 10.1186/1750-1172-1-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1172-1-6</ArticleId><ArticleId IdType="pmc">PMC1459118</ArticleId><ArticleId IdType="pubmed">16722594</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakano M, Iwasaki Y, Fujio K. Transcriptomic studies of systemic lupus erythematosus. Inflamm Regen. 2021;41:11. doi: 10.1186/s41232-021-00161-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41232-021-00161-y</ArticleId><ArticleId IdType="pmc">PMC8033719</ArticleId><ArticleId IdType="pubmed">33836832</ArticleId></ArticleIdList></Reference><Reference><Citation>Panousis NI, Bertsias GK, Ongen H, Gergianaki I, Tektonidou MG, Trachana M, et al. Combined genetic and transcriptome analysis of patients with SLE: distinct, targetable signatures for susceptibility and severity. Ann Rheum Dis. 2019;78(8):1079&#x2013;1089. doi: 10.1136/annrheumdis-2018-214379.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2018-214379</ArticleId><ArticleId IdType="pmc">PMC6691930</ArticleId><ArticleId IdType="pubmed">31167757</ArticleId></ArticleIdList></Reference><Reference><Citation>Newman AM, Steen CB, Liu CL, Gentles AJ, Chaudhuri AA, Scherer F, et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol. 2019;37(7):773&#x2013;782. doi: 10.1038/s41587-019-0114-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41587-019-0114-2</ArticleId><ArticleId IdType="pmc">PMC6610714</ArticleId><ArticleId IdType="pubmed">31061481</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA. Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol Biol. 2018;1711:243&#x2013;259. doi: 10.1007/978-1-4939-7493-1_12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-7493-1_12</ArticleId><ArticleId IdType="pmc">PMC5895181</ArticleId><ArticleId IdType="pubmed">29344893</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, Cui Y, Feng J, Guo Y. Identifying the pattern of immune related cells and genes in the peripheral blood of ischemic stroke. J Transl Med. 2020;18(1):296. doi: 10.1186/s12967-020-02463-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-020-02463-0</ArticleId><ArticleId IdType="pmc">PMC7398186</ArticleId><ArticleId IdType="pubmed">32746852</ArticleId></ArticleIdList></Reference><Reference><Citation>Karpi&#x144;ski P, Frydecka D, S&#x105;siadek MM, Misiak B. Reduced number of peripheral natural killer cells in schizophrenia but not in bipolar disorder. Brain Behav Immun. 2016;54:194&#x2013;200. doi: 10.1016/j.bbi.2016.02.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2016.02.005</ArticleId><ArticleId IdType="pubmed">26872421</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss E, de la Grange P, Defaye M, Lozano JJ, Aguilar F, Hegde, et al. Characterization of blood immune cells in patients with decompensated cirrhosis including ACLF. Front Immunol 2021;11:619039.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7893087</ArticleId><ArticleId IdType="pubmed">33613548</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang YH, Hou HA, Lin CC, Kuo YY, Yao CY, Hsu CL, et al. A CIBERSORTx-based immune cell scoring system could independently predict the prognosis of patients with myelodysplastic syndromes. Blood Adv. 2021;5(22):4535&#x2013;4548. doi: 10.1182/bloodadvances.2021005141.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2021005141</ArticleId><ArticleId IdType="pmc">PMC8759137</ArticleId><ArticleId IdType="pubmed">34614508</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao X, Zhang L, Wang J, Zhang M, Song Z, Ni B, You Y. Identification of key biomarkers and immune infiltration in systemic lupus erythematosus by integrated bioinformatics analysis. J Transl Med. 2021;19(1):35. doi: 10.1186/s12967-020-02698-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-020-02698-x</ArticleId><ArticleId IdType="pmc">PMC7814551</ArticleId><ArticleId IdType="pubmed">33468161</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y, Tang W, Tang W. Immune cell infiltration characteristics and related core genes in lupus nephritis: results from bioinformatic analysis. BMC Immunol. 2019;20(1):37. doi: 10.1186/s12865-019-0316-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12865-019-0316-x</ArticleId><ArticleId IdType="pmc">PMC6805654</ArticleId><ArticleId IdType="pubmed">31638917</ArticleId></ArticleIdList></Reference><Reference><Citation>Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725. doi: 10.1002/art.1780400928.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780400928</ArticleId><ArticleId IdType="pubmed">9324032</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Orbai AM, Alarc&#xf3;n GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677&#x2013;2686. doi: 10.1002/art.34473.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34473</ArticleId><ArticleId IdType="pmc">PMC3409311</ArticleId><ArticleId IdType="pubmed">22553077</ArticleId></ArticleIdList></Reference><Reference><Citation>Isenberg DA, Rahman A, Allen E, Farewell V, Akil M, Bruce IN, et al. BILAG 2004.&#x3a3; Development and initial validation of an updated version of the British Isles Lupus Assessment Group&#x2019;s disease activity index for patients with systemic lupus erythematosus. Rheumatology (Oxford) 2005;44(7):902&#x2013;6. doi: 10.1093/rheumatology/keh624.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keh624</ArticleId><ArticleId IdType="pubmed">15814577</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014;30(15):2114&#x2013;2120. doi: 10.1093/bioinformatics/btu170.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/btu170</ArticleId><ArticleId IdType="pmc">PMC4103590</ArticleId><ArticleId IdType="pubmed">24695404</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2012;29(1):15&#x2013;21. doi: 10.1093/bioinformatics/bts635.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/bts635</ArticleId><ArticleId IdType="pmc">PMC3530905</ArticleId><ArticleId IdType="pubmed">23104886</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren X, Kuan PF. RNAAgeCalc: a multi-tissue transcriptional age calculator. PLoS ONE. 2020;15(8):e.0237006. doi: 10.1371/journal.pone.0237006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0237006</ArticleId><ArticleId IdType="pmc">PMC7402472</ArticleId><ArticleId IdType="pubmed">32750074</ArticleId></ArticleIdList></Reference><Reference><Citation>Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550. doi: 10.1186/s13059-014-0550-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-014-0550-8</ArticleId><ArticleId IdType="pmc">PMC4302049</ArticleId><ArticleId IdType="pubmed">25516281</ArticleId></ArticleIdList></Reference><Reference><Citation>Pomaznoy M, Ha B, Peters B. GOnet: a tool for interactive gene ontology analysis. BMC Bioinformatics. 2018;19(1):470. doi: 10.1186/s12859-018-2533-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12859-018-2533-3</ArticleId><ArticleId IdType="pmc">PMC6286514</ArticleId><ArticleId IdType="pubmed">30526489</ArticleId></ArticleIdList></Reference><Reference><Citation>Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453&#x2013;457. doi: 10.1038/nmeth.3337.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.3337</ArticleId><ArticleId IdType="pmc">PMC4739640</ArticleId><ArticleId IdType="pubmed">25822800</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng Y, Cai B, Ren C, Xu H, Du W, Wu Y, et al. Identification of immune related cells and crucial genes in the peripheral blood of ankylosing spondylitis by integrated bioinformatics analysis. PeerJ. 2012;9:e12125. doi: 10.7717/peerj.12125.</Citation><ArticleIdList><ArticleId IdType="doi">10.7717/peerj.12125</ArticleId><ArticleId IdType="pmc">PMC8432305</ArticleId><ArticleId IdType="pubmed">34589304</ArticleId></ArticleIdList></Reference><Reference><Citation>Erkeller-Yuksel FM, Lydyard PM, Isenberg DA. Lack of NK cells in lupus patients with renal involvement. Lupus. 1997;6(9):708&#x2013;712. doi: 10.1177/096120339700600905.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/096120339700600905</ArticleId><ArticleId IdType="pubmed">9412985</ArticleId></ArticleIdList></Reference><Reference><Citation>Ronchetti S, Ricci E, Migliorati G, Gentil M, Riccardi C. How glucocorticoids affect the neutrophil life. Int J Mol Sci. 2018;19(12):4090. doi: 10.3390/ijms19124090.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms19124090</ArticleId><ArticleId IdType="pmc">PMC6321245</ArticleId><ArticleId IdType="pubmed">30563002</ArticleId></ArticleIdList></Reference><Reference><Citation>Northcott M, Gearing LJ, Bonin J, Koelmeyer R, Hoi A, Hertzog PJ, Morand EF. Immunosuppressant exposure confounds gene expression analysis in systemic lupus erythematosus. Front Immunol. 2022;13:964263. doi: 10.3389/fimmu.2022.964263.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.964263</ArticleId><ArticleId IdType="pmc">PMC9430375</ArticleId><ArticleId IdType="pubmed">36059457</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao L, Jiang Z, Jiang Y, Ma N, Wang K, Zhang Y. Changes in immune cell frequencies after cyclophosphamide or mycophenolate mofetil treatments in patients with systemic lupus erythematosus. Clinical Rheumatol. 2021;31(6):951&#x2013;959. doi: 10.1007/s10067-012-1958-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-012-1958-8</ArticleId><ArticleId IdType="pubmed">22349930</ArticleId></ArticleIdList></Reference><Reference><Citation>Eickenberg S, Mickholz E, Jung E, Nofer JR, Pavenst&#xe4;dt HJ, Jacobi AM. Mycophenolic acid counteracts B cell proliferation and plasmablast formation in patients with systemic lupus erythematosus. Arthritis Res Ther. 2012;14(3):R110. doi: 10.1186/ar3835.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar3835</ArticleId><ArticleId IdType="pmc">PMC4060361</ArticleId><ArticleId IdType="pubmed">22571761</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson GA, Peng J, D&#xf6;nnes P, Coelewij L, Naja M, Radziszewska A, et al. 2020. Disease-associated and patient-specific immune cell signatures in juvenile-onset systemic lupus erythematosus: patient stratification using a machine-learning approach. Lancet Rheumatol. 2020;2(8):e485&#x2013;496. doi: 10.1016/S2665-9913(20)30168-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(20)30168-5</ArticleId><ArticleId IdType="pmc">PMC7425802</ArticleId><ArticleId IdType="pubmed">32818204</ArticleId></ArticleIdList></Reference><Reference><Citation>Kandyil RM, Kamdar AA, Warren R, Hanson IC. Serial immunphenotyping and prolonged B cell dysfunction in systemic lupus erythematosus (SLE) treated with mycophenolate mofetil (MMF) J Allergy Clin Immunol. 2009;123(2):S162. doi: 10.1016/j.jaci.2008.12.611.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2008.12.611</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SY, Ryu SJ, Ahn HJ, Choi HR, Kang HT, Park SC. Senescence-related functional nuclear barrier by down-regulation of nucleo-cytoplasmic trafficking gene expression. Biochem Biophys Res Commun. 2010;391(1):28&#x2013;32. doi: 10.1016/j.bbrc.2009.10.154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2009.10.154</ArticleId><ArticleId IdType="pubmed">19903462</ArticleId></ArticleIdList></Reference><Reference><Citation>Lugar PL, Love C, Grammer AC, Dave SS, Lipsky PE. Molecular characterization of circulating plasma cells in patients with active systemic lupus erythematosus. PLoS ONE. 2012;7(9):e44362. doi: 10.1371/journal.pone.0044362.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0044362</ArticleId><ArticleId IdType="pmc">PMC3448624</ArticleId><ArticleId IdType="pubmed">23028528</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>